mYXpression begins a clinical trial to demonstrate the efficacy of RITI® rhumato

mYXpression begins a clinical trial to demonstrate the efficacy of RITI® rhumato, a test to help prescribe biotherapies for the treatment of rheumatoid arthritis.

The french start-up mYXpression, based in Dijon, has developed an In Silico technology intended to optimize the care of patients suffering from rheumatoid arthritis.

Using a patient’s blood sample, the RITI® rhumato test is able to establish an efficacy score for each biotherapy, based on the patient’s biology. Physicians can thus direct their prescriptions towards the biomedicine that will maximize the chances of achieving remission.

Having recently obtained the CE mark, mYXpression is starting a 234-patient clinical trial designed to demonstrate the relevance of the RITI® rhumato test in the management of rheumatoid arthritis. This is the last major step before the innovation is launched on the market, scheduled for 2025.

Professor FLIPO René-Marc (Regional University Hospital of Lille), coordinating investigator, will be leading the trial in collaboration with a dozen university and general hospitals throughout France.

“Our technology is far ahead of its time, and responds to a medical problem that has not yet been solved: the right treatment, for the right patient, at the right time. The ambition of the RITI® rheumatology test is to limit treatment wandering and identify the biotherapy that will help patients achieve remission”, emphasizes CEO Jean-François Prugnot.

Marion Pantin
Communication Manager